# EDGAR Filing Document

**Accession Number:** 0001419051
**File Stem:** 0001493152-23-005622
**Filing Date:** 2023-2
**Character Count:** 4449
**Document Hash:** 2378a793cd8a06c0ee968bf43df47c60
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-005622.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001493152-23-005622

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 25

**CONFORMED PERIOD OF REPORT**: 20230221

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
- **CENTRAL INDEX KEY:** 0001419051
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 451226465
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54554
- **FILM NUMBER:** 23647201

**BUSINESS ADDRESS:**
- **STREET 1:** 701 WILD ROSE LANE
- **CITY:** ELK CITY
- **STATE:** ID
- **ZIP:** 83525
- **BUSINESS PHONE:** (760) 295-7208

**MAIL ADDRESS:**
- **STREET 1:** 701 WILD ROSE LANE
- **CITY:** ELK CITY
- **STATE:** ID
- **ZIP:** 83525

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Friendly Auto Dealers, Inc.
- **DATE OF NAME CHANGE:** 20071120

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): February 21, 2023

---

| |
|:---|
| **THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.** |
| (Exact Name of Registrant as Specified in its Charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-54554** | **45-1226465** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

---

| |
|:---|
| **701 Wild Rose Lane**<br>**Elk City, Idaho 83525** |
| (Address of Principal Executive Offices and Zip Code) |
| **(760) 295-7208** |
| (Issuer's telephone number) |
| (Former Name or Former Address, if Changed Since Last Report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

On February 17, 2023, Therapeutic Solutions International, Inc. and Veltmeyer Institute for Advanced Biologics, LLC, entered into an exclusive patent license agreement for Right to Try, emergency Investigational New Drug ("IND"), and/or Expanded Access use within the field of brain and lung for those conditions that are applicable included here in exhibit 10.1. In exchange TSOI has received 30% of Veltmeyer Institute Management Company, LLC.

Item 8.01 Other Events.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference including reference to exhibits.

Item 9.01 Financial Statements and Exhibits.

Exhibit Index

(10.1) [Exclusive Patent License Agreement between Therapeutic Solutions International, Inc. and Veltmeyer Institute for Advanced Biologics, LLC](ex10-1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: February 21, 2023 | Date: February 21, 2023 |
| THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. |
| By: | */s/ Timothy Dixon* |
|  | Timothy Dixon |
|  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

![](ex10-1_002.jpg)

![](ex10-1_003.jpg)

![](ex10-1_004.jpg)

![](ex10-1_005.jpg)

![](ex10-1_006.jpg)

![](ex10-1_007.jpg)

![](ex10-1_008.jpg)

![](ex10-1_009.jpg)

![](ex10-1_010.jpg)

![](ex10-1_011.jpg)

![](ex10-1_012.jpg)